In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.

On Friday October 7 at 2 PM EST, Jan De Backer CEO of Fluidda, will present at the RESCON-summit in New York.

The presentation is entitled: “In-vitro/In-silico bio-equivalence trials as alternatives to clinical endpoint studies.” And comprises the following topics:

How can FRI help in cost reduction of the development of (generic) drugs?
Recent advances in in-silico and in-vitro measurements. (e.g., patient specific CFD models)

For more information on these topics, visit www.fluidda.com or send an email to [email protected]